An observational study in Tomography, sponsored by Alcon Research. Recruiting at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Alcon Research (part of Alcon) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Keratoconus with a site in United States — 27 open to participants now, 33 under way, 9 of them phase 3. Keratoconus · United States.
Among the 94 studies in Keratoconus with a site in United States, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2026, is one of 22 observational ones, reaches primary completion later than 11 of the 32 other live ones, and was the 91st registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →27 of the 94 studies in Keratoconus with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
Glaukos Corporation · Sites in United States
Ages 13+
Glaukos Corporation · Sites in United States
Ages 18–55
Price Vision Group · Sites in United States
Ages 10–90
Woolfson Eye Institute · Sites in United States
Ages 8+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 22 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 22 · Phase 3 29 · Phase 4 4
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is below the median of 130 across 97 observational studies indexed under Keratoconus.
Median enrollment 147 across the 71 interventional studies, 168 across the 21 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Alcon has 1 study filed under Keratoconus — fewer than ten, so there is no comparison to draw.
9 of the studies in Keratoconus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06235567Maanasa Indaram, MDDextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking | 2026-12 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT03760432Oregon Health and Science UniversityCollagen Cross-linking in Keratoconus | 2026-12 |
| NCT07400952Glaukos CorporationPlacebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | 2027-04 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 94 studies in Keratoconus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to validate the clinical measurement performance of an investigational biometer. Subjects will undergo multiple measurements of the eye, and the agreement, repeatability, and reproducibility of corneal and epithelial thickness maps will be evaluated.
The study population will consist of male and female adult subjects with normal corneas (approximately 30 subjects), keratoconus (approximately 20 subjects), prior corneal laser vision correction (approximately 20 subjects), current and habitual contact lens wear (approximately 20 subjects), and dry eye (approximately 20 subjects). In this single visit study, measurements will be taken by 3 different operators using their own set of devices (configuration), UNITY DX and ANTERION. Each subject's participation is expected to last approximately 3 hours with a planned duration of exposure generally not longer than 10 minutes per device. Only one eye (designated as the study eye) will be enrolled per subject.
Cohorts will be selected from approximately one investigative site located in the United States.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The eye will be imaged up to seven times with each biometer to achieve three acceptable scans. This cohort will enroll subjects with normal corneas.
Device: UNITY DX · Device: ANTERION
The eye will be imaged up to seven times with each biometer to achieve three acceptable scans. This cohort will enroll subjects with keratoconus.
Device: UNITY DX · Device: ANTERION
The eye will be imaged up to seven times with each biometer to achieve three acceptable scans. This cohort will enroll subjects with prior corneal laser vision correction.
Device: UNITY DX · Device: ANTERION
The eye will be imaged up to seven times with each biometer to achieve three acceptable scans. This cohort will enroll subjects with current and habitual contact lens wear.
Device: UNITY DX · Device: ANTERION
The eye will be imaged up to seven times with each biometer to achieve three acceptable scans. This cohort will enroll subjects with dry eye.
Device: UNITY DX · Device: ANTERION
Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties
Commercially available non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and their optical properties
Mean corneal thickness
Corneal thickness will be measured by the device and reported in microns. This outcome measure will be analyzed using Bland-Altman Limits of Agreement, Deming regression, repeatability and reproducibility.
Time frame: Day 1
Mean epithelial thickness
Epithelial thickness will be measured by the device and reported in microns. This outcome measure will be analyzed using Bland-Altman Limits of Agreement, Deming regression, repeatability and reproducibility.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 36 observational studies under Keratoconus, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 95. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.